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ABSTRACT [<250 words] 
 
Introduction 
Newly diagnosed glioblastoma is now commonly treated with surgery as feasible or biopsy, 
followed by radiotherapy plus concomitant and adjuvant temozolomide. The treatment of 
recurrent glioblastoma continues to be a moving target as new therapeutic principles enrich the 
standards of care for newly diagnosed disease.  
Methods 
We reviewed PubMed and ASCO abstracts from 2006 to January 2012 to identify clinical trials 
investigating the treatment of recurrent or progressive glioblastoma with nitrosoureas, 
temozolomide, bevacizumab, and/or combinations of these agents.  
Results 
At recurrence, a minority of patients are eligible for second surgery or reirradiation, based on 
appropriate patient selection. In temozolomide-pretreated patients, progression-free survival rates 
at 6 months of 20% to 30% may be achieved either with nitrosoureas, temozolomide in various 
dosing regimens, or bevacizumab. Combination regimens among these agents or with other 
drugs have not produced evidence for superior activity, but commonly more toxicity.  
Conclusion 
More research is needed to better define patient profiles that predict benefit from the limited 
therapeutic options available after the current standard of care has failed. 
 
Keywords: bevacizumab, glioblastoma, nitrosoureas, MGMT, temozolomide.  
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INTRODUCTION 
 
Glioblastoma is the most aggressive malignant primary brain tumor in adults (median age, 64 
years) with a preponderance in males (1.3 to 1.6:1) and whites and those of European descent 
(2:1 compared with African Americans).1,2 The annual incidence ranges from 3 to 5 newly 
diagnosed cases per 100 000 population. Therapeutic advances over the last decade have led to 
improvements in both patients’ life expectancy and quality of life. Based on data from the 
Surveillance, Epidemiology and End Results (SEER) program, median survival times of all 
patients with newly diagnosed glioblastoma improved from 8.1 months in 2000 to 2003 to 9.7 
months in 2005 to 2008, likely due to the introduction of temozolomide.3  
The current standard of care for patients with newly diagnosed glioblastoma was 
established in 2005, following the pivotal European Organization for the Research and 
Treatment of Cancer (EORTC)/National Cancer Institute of Canada Clinical Trials Group 
(NCIC-CTG) trial, where concurrent temozolomide (75 mg/m2/daily for up to 7 weeks) and 
radiotherapy followed by 6 maintenance cycles of adjuvant chemotherapy (150-200 mg/m2 5-day 
therapy every 28 days) led to improved progression-free survival (PFS) and overall survival 
(OS).4 Improved survival in this trial was largely restricted to a subset of patients harboring 
promoter methylation of the DNA repair gene O6-methylguanine-DNA methyltransferase 
(MGMT).5 In a recent phase 3 trial of 833 eligible patients, no significant improvement in 
median OS (16.6 vs 14.9 mo; P = 0.63) or median PFS (5.5 vs 6.7 month; P = 0.06) was found 
for patients who received dose-dense extended temozolomide (75 mg/m2 21-day therapy every 4 
weeks for 6-12 cycles) plus radiotherapy compared with patients who received standard-dose 
temozolomide plus radiotherapy, respectively, regardless of methylation status.6 However, 
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MGMT promoter methylation was associated with improved median PFS (8.7 vs 5.7 months; P < 
0.0001) and OS (21.2 vs 14 months; P < 0.0001).6 Despite standard of care therapy,7 recurrence 
rates remain high in patients with glioblastoma (~90%). Median OS is 15 to 18 months in 
clinical trial populations, and <10% are alive at 5 years.1  
The primary purpose of this paper is to discuss the role of second-line monotherapy and 
combination therapies for patients with recurrent or progressive glioblastoma. What is the 
current role of nitrosoureas, alone or in combination? Does efficacy outweigh their toxicity 
profile? We will also address the efficacy of the varied metronomic temozolomide dosing 
regimens for rechallenge (ie, patients re-exposed to temozolomide who had been previously 
treated, or patients switched to alternative dosing regimens of temozolomide following signs of 
relapse or progression on standard temozolomide therapeutic regimens) as well as for 
temozolomide-naïve patients. The availability of bevacizumab, alone or in combination, to treat 
recurrent disease is another relatively new option that requires perspective. 
Numerous other issues must be considered when attempting to establish a standard of 
care for patients with recurrent glioblastoma. How is recurrence best determined? Which patients 
qualify for second surgery or repeat radiotherapy? Which patients should not be retreated at all? 
How should efficacy of treatment for recurrent glioblastoma be assessed in clinical trials? Is 6-
month PFS the optimal end point? Also, the prognostic value of the MGMT status in patients 
with recurrent glioblastoma is not well defined. Does MGMT status guide the selection of the 
appropriate agent at recurrence? Are other markers useful? 
 
Diagnosis of Progression 
Neuroimaging (serial MRI) remains the primary monitoring tool for glioblastoma with 
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assessments typically performed every 2 to 3 months during treatment and somewhat longer 
intervals during disease progression-free periods. However, standard MRI contrast studies, even 
when adhering to Macdonald criteria,8 may be misleading and confound the diagnosis of 
recurrence. Within the first months following completion of radiotherapy and concomitant 
temozolomide, it can be difficult to distinguish recurrence from pseudoprogression when using 
typical MRI modalities, e.g., T2, T1 with gadolinium, and fluid-attenuated inversion recovery 
(FLAIR).9 Pseudoprogression refers to an apparent increase in the tumor size that does not 
reflect tumor progression biologically and can only be proven post hoc if no further tumor-
specific treatment is administered at the time point of pseudoprogression and the lesion 
subsequently regresses. MRI patterns suggestive of pseudoprogression have been described in 
20% to 30% of patients treated with RT/TMZ→TMZ.10,11 Furthermore, radionecrosis 
characterized by blood-brain barrier disruption, edema, and mass effect mimicking progression 
appears earlier in these patients versus those treated with radiotherapy alone.11 Both 
pseudoprogression and radionecrosis are likely related and consistent with the increased tumor 
cell killing caused by chemoradiotherapy or increased host normal tissue responses, including 
blood-brain barrier breakdown, ischemia, effects of steroid withdrawal, and inflammation.9 
Nonetheless, the recurrence of glioblastoma remains predominantly local.12,13  
Currently, the roles of single photon emission-computed tomography (SPECT), positron 
emission tomography (PET), MR spectroscopy, and functional MRI in determining progression 
are being evaluated At present, we would advocate careful reimaging in case of suspected 
pseudoprogression. With no or minimal new symptoms, any rapid change of treatment is 
discouraged. Ultimately, some patients may need a biopsy if a definitive diagnosis needs to be 
established. In any case, before diagnosing pseudoprogression, it must be ascertained whether 
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the scans selected for comparison are appropriate, eg, a postsurgical scan may not be useful to 
assess progression at the first scan after concomitant radiochemotherapy if that patient started 
radiotherapy only 4 to 6 weeks after surgery. Moreover, the first scan after radiochemotherapy 
should be considered as a new baseline for all further imaging assessments. 
 
Radiographic Assessment of Treatment Response 
Efficacy evaluation of treatment in recurrent glioblastoma commonly relies on neuroimaging, 
supported by clinical monitoring, but can be complicated. A complete resolution of blood-brain 
disturbance detected by contrast extravasation on MRI or CT will no longer qualify as a response 
if there is increased T2 or FLAIR abnormality. Such responses are now referred to as 
“pseudoresponses.” The new Response Assessment in Neuro-Oncology (RANO) criteria, which 
integrate at least a qualitative measure for T2/FLAIR changes, appear to be an improvement over 
the Macdonald criteria and may facilitate the interpretation of therapeutic outcomes in patients 
with glioblastoma (Table 1).14,15 In contrast to the Macdonald criteria, measurable and 
nonmeasurable lesions are defined, and tumor size is measured on T2-/FLAIR-weighted images 
in addition to the contrast-enhancing tumor. The RANO criteria also establish criteria for entry 
into clinical trials for recurrent high-grade glioma. For a first progression that allows screening 
for a recurrent therapy trial, time from initial chemoradiotherapy is pivotal. Patients will not be 
formally considered progressors within the first 3 months from the end of radiochemotherapy. 
Also, RANO criteria provide definitions of radiographic response that incorporate changes in 
non-enhancing lesions. For suspected cases of pseudoprogression not only in the context of 
temozolomide-based radiochemotherapy, but also in new therapies, notably local therapies, that 
influence the vascular biology of malignant gliomas, a close control MRI and clinical 
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examination are recommended. The RANO criteria are likely to be valuable when assessing 
treatment response in clinical trials as well as for monitoring patients in daily practice, but will 
require further validation. 
 
Role of Repeat Surgery and Radiotherapy 
About 1 in 4 patients with progressive or recurrent glioblastoma can be considered for 
repeat surgery. The benefits of reoperation have primarily been derived from retrospective 
studies. A more favorable prognosis following surgery for recurrence or progression is 
associated with younger age (<70 years), smaller tumor volume (<50 cm3), and a preoperative 
KPS >80%.16,17 Repeat surgery is not recommended for patients with involvement of 
prespecified eloquent/critical brain regions.17 A controversial practice at the time of repeat 
surgery is the implantation of biodegradable chemotherapy wafers containing carmustine, which 
may prolong survival, but are rarely used today.7,18  
Reirradiation remains a palliative option for a select group of patients with recurrent 
glioblastoma. Patients with a KPS of >60%, a tumor size of <30 to 40 mm, and progression >6 
months from time of surgery appear to be the best candidates.19 The most common approach 
involves the use of fractionated stereotactic radiotherapy with or without intensity modulation 
and a median total dose of 30 to 36 Gy.20 In contrast, stereotactic radiosurgery, the 
administration of one single fraction, which has the theoretical advantage of sparing normal 
tissue, is rarely used in glioblastoma because of the poorly defined target volume. Interestingly, 
none of the reirradiation schedules has ever been looked at in a prospective or controlled fashion. 
In fact, the recent APG101 trial provided no sign of efficacy for reirradiation at 18 x 2 Gy in 
recurrent glioblastoma patients commonly deemed best candidates for that intervention.21 
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Monotherapy and Combination Chemotherapeutic Trials for Recurrent Disease 
Over the last decade, an increased number of clinical trials have evaluated the benefits of single 
agent and combination chemotherapy to treat patients with recurrent or progressive glioblastoma. 
Older studies usually evaluated a heterogeneous patient population, including those with a mix of 
WHO grade III/IV gliomas. Older series often reported on therapeutic options in temozolomide-
naïve patients, whereas more recent studies included only those pretreated with temozolomide. 
Almost all study designs were noncomparative or failed to include an adequate control arm. The 
majority considered 6-month PFS rate and median OS from the time of recurrence as the primary 
end points. Although the 6-month PFS rate is advocated as a reliable measure of tumor control 
and a strong predictor of survival,22 it is influenced by further salvage therapies. Radiographic 
responses were often incompletely reported with most studies using the Macdonald criteria to 
assess response. Finally, interpretation of efficacy findings, specifically comparison between 
independent publications, may be confounded by other factors, including whether reirradiation or 
repeat surgery were performed as well as number of previous relapses, general health status, age, 
and other underlying factors. 
 This report is a systematic review, which used PubMed and ASCO abstract reports from 
2006 to January 2012 as the primary sources of data. The objective of the analysis was to 
identify clinical efficacy trials following systemic treatment with nitrosoureas, temozolomide, 
bevacizumab, and/or combinations of these agents in patients with recurrent or progressive 
glioblastoma. No specific limitations were placed on the selection of studies given the relative 
paucity of data. 
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Nitrosoureas—single and combination therapy. Nitrosoureas are DNA alkylating agents 
characterized by high lipophilicity, which permit blood-brain barrier penetration, making them 
useful in the treatment of brain tumors. Prior to 1999, nitrosoureas (eg, carmustine [BCNU], 
lomustine [CCNU] and nimustine [ACNU]) were commonly used in the first-line treatment of 
glioblastoma. Another alkylating agent, procarbazine, was used alone or in combination with 
CCNU. In 1999, two phase 2 trials changed the therapeutic landscape when temozolomide was 
found to be efficacious for recurrent glioblastoma patients who had received no more than 1 
course of nitrosourea-based chemotherapy.23,24 These data, coupled with the favorable 
tolerability profile of temozolomide, led to its approval in 1999 for recurrent high-grade gliomas, 
and nitrosoureas were moved into second line. Subsequently, temozolomide became the 
treatment of choice for newly diagnosed glioblastoma in 2005. Despite the less than optimal 
safety profile of nitrosoureas, e.g., bone marrow suppression, liver/renal toxicity, and interstitial 
lung disease, they remain a second-line treatment option in single and combination regimens for 
recurrent disease (Table 2).  
 Two phase 2 trials25,26 and 1 retrospective series27 evaluated a similar carmustine 
monotherapy regimen for recurrent/progressive disease in 104 patients, some of whom had 
received prior temozolomide therapy. The 6-month PFS and median OS for 2 studies ranged 
from 13.0% to 17.5% and 5.1 to 7.5 months, respectively; no complete remissions were 
observed.26,27 Efficacy end points for one study were unevaluable (data not presented separately 
for carmustine).25 The predominant side effects following carmustine monotherapy were 
hematologic and long-lasting hepatic and pulmonary toxicity (Table 2). 
 A recent prospective phase 3 trial in 92 lomustine-treated patients (70 at first relapse) 
reported a 19% 6-month PFS response rate with a median OS of 7.1 months.28 Grade 3 and 4 
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hematologic toxicities were very common (46 events) with thrombocytopenia and neutropenia 
reported most often. In a double-blind, randomized, multicenter phase 3 trial of 325 patients who 
received prior radiation and temozolomide, the lomustine monotherapy arm (n = 65) provided a 
6-month PFS rate and median OS of 24.5% and 9.8 months.29,30 Grade 3 and 4 
thrombocytopenia, leukopenia and lymphopenia were common. 
 In a small retrospective report, nimustine (ACNU) in temozolomide-pretreated patients 
was given alone (n = 14) or in combination with teniposide (n = 17) or cytarabine (n = 1).31 The 
6-month PFS rate for all 32 patients was 20%, and the median OS from the start of nimustine 
therapy was 6.7 months. Fifty percent of patients developed grade 3 or 4 hematologic toxicity. 
No patient developed pulmonary fibrosis. 
Fotemustine is another nitrosourea compound mostly studied in Europe, notably Italy and 
France.32 Four prospective phase 2 trials, using slightly different induction/maintenance dosage 
regimens, evaluated fotemustine in temozolomide-pretreated patients with recurrent or 
progressive glioblastoma.33-36 Two studies were exclusively in patients experiencing their first 
relapse.33,35 Overall, 6-month PFS and median OS ranged from 20.9% to 61% and 6.0 to 11.1 
months, respectively. The best findings were obtained with a protracted low-dose induction 
regimen and the administration of fotemustine at least 3 months after completing first-line 
temozolomide therapy.33 Grade 3 and 4 hematologic toxicities were commonly reported 
following fotemustine therapy; however, lower rates were observed33 perhaps due to the 
implementation of a longer rest period (2 weeks) between doses during the induction phase. The 
small sample sizes in each of these studies call for larger prospective trials to ascertain the 
efficacy and safety of fotemustine in a temozolomide-pretreated population with recurrent 
glioblastoma. 
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Little data are published that assess nitrosourea combination therapies for recurrent 
disease. Two retrospective studies (1994-2003), encompassing nearly 150 patients of whom 16 
received front-line temozolomide, evaluated the combination of procarbazine, lomustine, and 
vincristine.37,38 Similar efficacy findings were reported in the 2 reports: 30% to 38% PFS at 6 
months and 7.6 to 7.9 months OS. While grade 3/4 hematologic toxicity was common (26%), 
nonhematologic toxicity was mild, and pulmonary fibrosis was not reported.37 Lomustine in 
combination with cediranib (n = 129) was not found to be more effective (6-month PFS, 34.5%; 
median OS, 9.4 months) than lomustine given alone (see above).29,30 However, grade 3 and 4 
hematologic and nonhematologic toxicities were substantially greater with combination versus 
either monotherapy arm.  
Significant hematologic toxicity concerns and the availability of more effective agents 
have made the use of nitrosoureas overall less desirable. New schedules at lower doses may 
prove beneficial. The nitrosoureas seem comparable in terms of efficacy at clinically tolerated 
doses, whereas nonhematologic toxicity, notably lung fibrosis, may be more common with 
carmustine than with lomustine or nimustine. 
 
Temozolomide monotherapy trials. Numerous trials have evaluated the efficacy and safety of 
temozolomide as monotherapy for recurrent or progressive disease, albeit few of the trials were 
conducted as prospective randomized controlled designs (Table 3).  
Nine trials evaluated temozolomide monotherapy given in traditional (5-day/cycle) and 
novel schedules in 372 temozolomide-naïve patients with recurrent disease.24,39-46 Generally, 
patients were being treated for first or second relapses. Approximately half of the patients had 
received previous chemotherapy, mostly nitrosourea-based; the remainder was managed with 
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surgery and radiotherapy as first-line treatment. Five of these studies administered temozolomide 
in traditional 5-day/cycle regimens with doses ranging from 150 to 200 mg/m2.24,39,40,42,44 Novel 
metronomic temozolomide schedules (75-100 mg/m2 once or twice a day for 21-42 consecutive 
days using 28- to 70-day cycles) were used in 3 studies. 41,43,45. A 1-week-on/1-week-off 
schedule of temozolomide 150 mg/m2 was investigated in one study, in which promising 6-
month PFS rates approaching 50% were observed.46,47 Across all 9 studies, 6-month PFS rates 
ranged from 18% to 48% and median OS was 5.4 to 9.9 months. Notably, survival appeared 
higher by about 2 months in the more recent studies,43-45 which may be due to other changes in 
the standard of care of glioblastoma patients or due to patient selection. 
Six studies, conducted in 162 temozolomide-pretreated patients, evaluated temozolomide 
rechallenge.48-53 A variety of metronomic schedules were employed, including 40 to 100 mg/m2 
daily doses given for 21 to 365 consecutive days as well as alternating 1-week-on/1-week-off 
regimens. Overall, the 6-month PFS rate and median OS ranged from 23% to 58.3% and 5.1 to 
13 months, respectively.  
One retrospective analysis compiled data on 5 different temozolomide dosing regimens 
among 47 patients (re)challenged while receiving adjuvant temozolomide or after a 
temozolomide-free interval (Table 3).54 The 6-month PFS rates were 26.3% and 28.6% for 
patients progressing on temozolomide versus after temozolomide. The corresponding median OS 
was 6.6 and 5.3 months, respectively.  
Of particular note, the RESCUE study examined the benefits of temozolomide 
rechallenge based on the “temozolomide-free interval”, i.e., time between upfront treatment and 
rechallenge.51 The 6-month PFS rate and median OS were 27.3% and 3.6 months for patients 
receiving rechallenge early (progression while receiving adjuvant temozolomide before 
Standard of Care for Recurrent Glioblastoma Page 14 of 75  
completion of 6 cycles of adjuvant temozolomide); 7.4% and 1.8 months for patients receiving 
rechallenge after an extended period (progression while receiving extended adjuvant 
temozolomide beyond the standard 6 cycles but before completion of adjuvant treatment); and 
35.7% and 3.7 months for patients receiving rechallenge after a prolonged interval (progression 
after completion of adjuvant treatment and a treatment-free interval of greater than 2 months). 
Patients who experienced early progression derived the most benefit from temozolomide 
rechallenge therapy. The authors considered the possibility that the results in this early 
rechallenge group could be in part attributable to pseudoprogression but noted that the study was 
intentionally designed to exclude patients who progressed within the first 12 weeks following 
completion of chemoradiation, in keeping with the RANO criteria. Furthermore, the median time 
from the end of radiotherapy in this early group was 5.2 months, thus minimizing the influence 
of pseudoprogression on these results. 
Three randomized clinical trials were conducted using single agent temozolomide.23,55,56 
In one study, a standard temozolomide regimen was more efficacious than procarbazine (6-
month PFS, 21% vs 8%) with a median 1.5 month longer survival time.23 The latter study was 
conducted in temozolomide-naïve patients and led to the approval of temozolomide for recurrent 
glioblastoma in Europe, although not in the United States. The BR12 study did not provide 
separate data for glioblastoma patients, but indicated that temozolomide dose-intense regimens 
do not provide a survival or PFS benefit compared with standard doses when treating 
temozolomide-naïve patients. The DIRECTOR trial evaluated 2 dose-intense regimens of 
temozolomide (ie, 120 mg/m2/d 1 week on/1 week off vs 80 mg/m2/d 3 weeks on/1 week off) in 
patients experiencing a first relapse after at least 2 cycles of temozolomide.56 Specifically, 
patients were enrolled based on first progression of glioblastoma documented by MRI no earlier 
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than 180 days after first surgery and no earlier than 90 days after completion of radiotherapy. 
Data are currently maturing. 
Toxicity following single agent temozolomide therapy after rechallenge is outlined in 
Table 3. Grade 3 and 4 hematologic adverse events were reported in most studies, although there 
was no evidence of cumulative toxicity. Considering the small numbers of patients in most 
studies and the wide range of temozolomide regimens tested, there was no evidence that one 
metronomic schedule was advantageous over another in terms of safety. 
 
Bevacizumab monotherapy trials. Bevacizumab is a human recombinant monoclonal antibody 
to vascular endothelial growth factor (VEGF), a critical mediator of tumor angiogenesis.57,58 
Bevacizumab was approved in 2009 by the US FDA for the treatment of recurrent glioblastoma 
based on response	rate	with	durable	responses relative to historical controls from 
noncomparative phase 2 trials59,60; it is also available for use in various other countries 
throughout the world, but not in the European Union. The rejection in Europe was based on the 
absence of a randomized trial with a bevacizumab-free control arm. 
Three prospective phase 2 trials and 1 retrospective analysis have evaluated bevacizumab 
monotherapy in 233 temozolomide pretreated patients with recurrent or progressive disease 
(Table 4).59-62 Three studies used an identical dosing regimen (10 mg/kg IV every 2 
weeks),59,60,62 whereas one study administered 15 mg/kg every 3 weeks.61 The 6-month PFS rate 
ranged from 25% to 42.6% with a median OS of 6.5 to 9.2 months (Table 4). Radiographic 
responses were encouraging with complete and partial responses reported in 62/183 patients 
(33.9%).59,60,62 Grade 3 and 4 toxicity across the 4 studies was primarily nonhematologic and 
included hypertension, thromboembolic events, and fatigue. Prospective phase 3 studies would 
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be needed to determine more clearly the role of bevacizumab in the management of patients with 
recurrent or progressive glioblastoma. Meanwhile, data from two large randomized trials, 
AVAglio and RTOG-0825, adding bevacizumab to temozolomide chemoirradiation are likely to 
shape the future standards of care both at diagnosis and at recurrence. 
 
Other antiangiogenic agents. Various novel agents targeting potential regulators critical to 
glioblastoma cell growth, invasion, and angiogenesis have been evaluated in phase 2 trials in 
patients with recurrent disease. The VEGFR inhibitor cediranib was explored in patients with 
recurrent glioblastoma in a very sophisticated fashion using advanced neuroimaging and 
biomarkers studies.63,64 The PFS rate at 6 months of 31 patients with recurrent glioblastoma 
treated with cediranib monotherapy at a starting dose of 45 mg/d was 25.8%. Response rates 
were 56.7% for 3-dimensional measurements and 27% for 2-dimensional measurements. 
Toxicities were moderate. Changes in plasma placental growth factor, basic fibroblast growth 
factor, matrix metalloproteinase (MMP)-2, soluble VEGF receptor 1, stromal cell–derived 
factor-1, and soluble Tie2, and in urinary MMP-9/neutrophil gelatinase-associated lipocalin 
activity in response to cediranib were associated with radiographic response or survival.64 
Aflibercept (VEGF trap), a recombinant fusion protein that inhibits both VEGF and placental 
growth factor, was administered to 42 patients with recurrent glioblastoma at first relapse.65 
Efficacy of VEGF trap as a single agent for recurrent disease was minimal with a 6-month PFS 
rate of 7.7%, although 2 patients had durable response (alive at >150 weeks). Furthermore, grade 
3 nonhematologic toxicity was common and included fatigue and hypertension. XL184, an 
inhibitor of MET, VEGFR2, and RET, was given PO (125 mg or 175 mg/d) to 124 patients with 
recurrent glioblastoma.66 Modest activity was observed in patients with and without prior 
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antiangiogenic exposure. Overall, the interim 6-month PFS rates for the 125-mg and 175-mg 
cohorts were >25% and 21%, respectively.67 The most common grade 3 and 4 toxicities were 
fatigue (23%), hypophosphatemia (10%), serum lipase elevation (10%), and ALT elevation, 
headache, lymphopenia, and convulsion (9% each). 
Cilengitide, an inhibitor of v3 and v5 integrin receptors, showed modest single agent 
activity, i.e., 6-month PFS of 15% and median OS of 9.9 months, following a 2000 mg twice-
daily continuous regimen among 40 patients with recurrent glioblastoma (Table 4).68 Significant 
hematologic or nonhematologic toxicities following single agent cilengitide therapy were 
uncommon. Another phase 2 trial among 26 evaluable patients with recurrent glioblastoma also 
found that cilengitide was only modestly effective (ie, 6-month PFS of 12%).69  
 
Temozolomide-containing combination trials. Over the last decade, more than a dozen phase 1 
and 2 studies have investigated the efficacy and safety of temozolomide in combination with 
bevacizumab,70,71 nitrosoureas,72,73 and interferon74 as well as a plethora of 
conventional/miscellaneous chemotherapeutic agents, e.g., irinotecan, pegylated doxorubicin, 
cisplatin, capecitabine or sorafenib, for recurrent or progressive glioblastoma (Table 5).75-85 In 
general, the efficacy findings following temozolomide combination therapy failed to indicate a 
significant advantage over temozolomide or bevacizumab monotherapy regimens. However, 
evaluation of these studies is hampered by small sample sizes, heterogeneous study populations 
(temozolomide-naïve vs -pretreated; varied number of recurrences; number and type of prior 
therapies; time from last treatment to progression), and various temozolomide dosing regimens. 
Several recently conducted combination studies in temozolomide-pretreated patients deserve 
mention. 
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 Desjardins and colleagues evaluated the combination of protracted temozolomide (50 
mg/m2 daily) and bevacizumab (10 mg/kg intravenously every 2 weeks) in 32 temozolomide-
pretreated patients who predominantly were experiencing a first or second recurrence (94%).71 A 
radiographic response (all partial) was observed in 9/32 (28%) patients. The 6-month PFS rate 
was 18.8% with a median OS of 8.7 months. Not surprisingly, patients not receiving 
dexamethasone had a significantly higher 6-month PFS rate compared with those receiving 
steroids (31.3% vs 6.3%; P = 0.03). No difference in survival was observed between patients 
who had experienced disease progression on 5-day temozolomide before enrollment versus those 
who did not progress on 5-day temozolomide. MGMT status, determined in 21 patients, did not 
appear to be related to outcome. The regimen was well tolerated and characterized primarily by 
nonhematologic toxicities; 2 patients discontinued therapy secondary to toxicity (prolonged 
thrombocytopenia and grade 4 pancreatitis). 
 Gaviani and colleagues evaluated the combination of temozolomide and fotemustine in 
10 patients with recurrent disease following chemoradiation.73 The study was terminated early 
(planned enrollment of 105) because of severe hematologic toxicities (predominantly grade 3 and 
4 thrombocytopenia and granulocytopenia). The authors concluded that this combination does 
not merit further study. 
 A protracted daily temozolomide (50 mg/m2 daily) plus sorafenib regimen had very 
limited activity, despite a good safety profile, in 32 patients with recurrent disease.75 Only one 
patient achieved a partial response. The 6-month PFS rate was very low (9.4%). Importantly, 
~50% of enrolled patients had 2 or more prior progressions and had progressed while receiving 
5-day temozolomide, and more than one-third of patients had failed either prior bevacizumab or 
VEGFR inhibitor therapy. Despite potentially complementary direct and indirect mechanisms of 
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antitumor activity, the temozolomide/sorafenib combination was not effective in this phase 2 
trial. The poor results may be attributed to heavy pretreatment, higher failure rate to previous 
bevacizumab therapy, lack of selection of patients with sorafenib target expression, and the 
relatively high use of CYP3A-inducing antiepileptic drugs that may have compromised sorafenib 
activity. 
 The combination of temozolomide and afatinib (40 mg/d), an irreversible blocker of the 
epidermal growth factor receptor, was investigated in a phase 2 study.82 The 6-month PFS rate 
by independent review was 10% for the combination compared with 3% for patients receiving 
afatinib alone (P = 0.008) and 23% for patients given temozolomide alone (P = 0.59). Serious 
adverse events (≥ grade 3) for the combination were primarily nonhematologic (eg, diarrhea and 
skin reactions). 
A retrospective study in 28 patients (of whom 24 received temozolomide pretreatment) 
found that the combination of continuous low-dose temozolomide (10 mg/m2 twice daily) and 
celecoxib (200 mg daily) had some activity in treating recurrent glioblastoma without significant 
toxicity.84 The majority of patients (86%) were being treated for their first recurrence. Notably, 
19 (68%) patients underwent resection before retreatment. The 6-month PFS rate was 43%. 
MGMT promoter methylation did not predict a favorable outcome. The only severe toxicity was 
grade 3 lymphopenia in one patient. 
The combination of temozolomide and O6-benzylguanine, a MGMT-depleting agent, was 
tested in 34 patients with recurrent disease.83 One patient responded to this regimen. The 6-
month PFS rate was low (9%) with a median OS of 4.5 months. This 1-day temozolomide 
combination regimen failed to restore temozolomide sensitivity in patients with recurrent 
glioblastoma.  
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Overall, the temozolomide combination studies available to date do not suggest that one 
particular chemotherapy combination regimen is more effective than administration of 
temozolomide alone. 
 
Bevacizumab-containing combination trials. In addition to the studies that evaluated 
bevacizumab in combination with temozolomide (see section above), another series of studies 
have been conducted, which evaluated bevacizumab and miscellaneous other agents, including 
irinotecan, carboplatin, etoposide, erlotinib, and cetuximab, in patients with recurrent 
glioblastoma (Table 6).59,86-97 Unfortunately, the bevacizumab combination studies performed on 
a background of standard surgery, radiotherapy, and concurrent/adjuvant temozolomide therapy 
did not provide clear insight into new options for recurrent disease. Six studies in 357 evaluable 
patients, including one retrospective analysis, evaluated bevacizumab in combination with 
irinotecan.59,88,89,92,94,96 In theory, the combination of irinotecan and bevacizumab might improve 
efficacy due to a synergy of antiangiogenic and cytostatic properties. Most trials employed a 10 
mg/kg bevacizumab dosage regimen (range, 5-15 mg/kg) repeated every 2 weeks. Irinotecan was 
administered every 2 weeks in dosages of 125 without or 340 mg/m2 with coadministration of 
enzyme-inducing antiepileptic drugs. Overall, the 6-month PFS rate was 30.0% to 50.3% with a 
median OS of 6.1 to 9.7 months. One phase 2 trial provided 6-month PFS rates stratified by 
patients experiencing first and second recurrences: 49% and 57.1%, respectively.59 Overall, no 
additional benefit of irinotecan over that of bevacizumab alone became apparent. 
Another small phase 2 study (32 evaluable patients) tested the triple combination of 
bevacizumab, irinotecan, and cetuximab in patients experiencing a first relapse within 6 months 
of standard temozolomide therapy.87 Complete and partial responses were achieved in 2/32 
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(6.3%) and 9/32 (28.1%) patients, respectively. The 6-month PFS rate was 33% with a median 
OS of 7.0 months. A total of 4 and 20 grade 3/4 hematologic and nonhematologic events were 
reported, respectively. The addition of cetuximab was relatively well tolerated, except for skin 
toxicity; however, overall efficacy did not appear to be enhanced with the addition of cetuximab 
to the bevacizumab and irinotecan combination regimen.  
A retrospective analysis of triple combination therapy with bevacizumab, carboplatin, 
and etoposide included 6 patients treated at first (n = 2), second (n = 2), third (n = 1), or fourth (n 
= 1) recurrences.86 All patients had received focal radiation therapy and concurrent and adjuvant 
temozolomide following initial diagnosis and surgical intervention. Following 2 to 3 cycles of 
the triple drug regimen, a partial response was achieved in 5/6 patients. The combination was 
generally well tolerated. However, only marginally improved survival end points were reported: 
22% 6-month PFS rate and a median OS of 6.9 months. Recurrent tumor was found in 4/5 
patients with an initial response.  
Reardon and colleagues evaluated the efficacy of bevacizumab and etoposide among 27 
patients with primarily first recurrences (n = 14).91 A complete and partial response was 
observed in one and 6 patients, respectively. A 44.4% 6-month PFS rate and a median OS of 
10.2 months were reported. Notably, high VEGF expression (>30% of cells; P = 0.006) detected 
by immunochemistry of archival, paraffin-embedded tumor sections was associated with a better 
PFS.  
Sathornsumete and colleagues evaluated bevacizumab in combination with erlotinib, an 
epidermal growth factor receptor tyrosine kinase inhibitor, in a phase 2 study of 24 evaluable 
temozolomide-pretreated patients with recurrent glioblastoma.90 The 6-month PFS rate and 
median OS were 29.2% and 10.3 months, respectively. Survival end points of patients treated >3 
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months post radiotherapy were similar to the overall population. In summary, this combination 
did not appear to provide improved survival benefits when compared with historical 
bevacizumab-containing regimens. 
Bevacizumab was also studied in combination with hypofractionated stereotactic 
radiotherapy in a small pilot study.98 The investigators hypothesized that bevacizumab might 
increase tumor sensitivity to radiotherapy via depletion of VEGF and reduction of its signaling. 
Among 20 evaluable patients with recurrent glioblastoma (median number of recurrences, 1), the 
6-month PFS rate was 65% with a median OS of 12.5 months. Most patients had reirradiation in 
the same local region as originally treated. The combination was well tolerated with no unusual 
adverse events in this heavily pretreated population. Notably, this bevacizumab/radiotherapy 
combination was superior to findings from another study, where patients received reirradiation 
alone for recurrent disease.99 This approach deserves further consideration for the minority of 
eligible patients. 
 
Significance of MGMT Promotor Methylation Status in Recurrent Disease 
MGMT, a cellular DNA repair protein, rapidly reverses methylation via its suicide 
inactivation, thereby minimizing mutations and replication errors and restoring normal cellular 
homeostasis.100-102 Patients whose tumors have a methylated MGMT promoter, which probably 
results in	lower MGMT protein levels, are more likely to respond to alkylating agents because 
the tumor cells are unable to repair chemotherapy-induced DNA damage.103,104  
A direct, real-time methylation-specific PCR assay (MSP) is the current preferred method 
for determining the MGMT status.105 The MSP assay detects CpG island methylation with high 
sensitivity and specificity in clinical samples and has been shown to be highly reproducible 
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compared with the clinically validated nested, gel-based assay.5 At present, methylation assays 
remain the most reliable technique for assessing the prognostic impact of MGMT status. 
Two important issues are evident regarding the MGMT status and recurrent glioblastoma: 
1) whether changes in status occur between primary and recurrent glioblastoma and 2) whether 
positive status correlates with better outcome following recurrent disease.  
Among 80 patients with recurrent glioblastoma, including 64 patients treated with 
radiotherapy and temozolomide after the first operation, changes in MGMT promoter 
methylation status using the MSP technique were rarely found.106 Overall, 88.8% of patients 
showed an unchanged methylation status upon comparison of individual pairs of primary and 
recurrent glioblastomas. Seven patients (8.8%) showed loss or reduction of MGMT promoter 
methylation at recurrence. These findings suggest that MGMT retesting is unnecessary in patients 
with recurrence. Notably, the prognostic significance of the MGMT status was upheld for 
patients experiencing a recurrence. Significantly longer PFS and OS were found in patients with 
MGMT promoter-methylated tumors and correlated with favorable outcome under salvage 
alkylating chemotherapy. 
A preliminary report found that patients with a methylated MGMT status had a higher 
median PFS of 7.4 months compared with an unmethylated status (2 months; P = 0.08).53 
Median OS was also significantly higher in patients with MGMT-methylated tumors (16 months 
vs 11.5 months; P = 0.05). Additionally, the probability of achieving a radiographic response 
(PR/SD) was higher in patients with MGMT promoter methylation (P = 0.03).  
Among 24 patients with MGMT status determined by MSP, the disease control rate was 
greater in patients with tumors with a methylated (3/7; 42%) as opposed to an unmethylated 
(6/17; 35%) MGMT promoter.33 A trend toward a prolonged 6-month PFS was also observed; 
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however, neither end point achieved statistical significance. 
In a prospective report conducted from 2005 to 2007, which included 22 patients who 
had recurrent glioblastoma and who underwent surgery with carmustine wafer implantation, 
methylated MGMT status determined by MSP was correlated with better outcome.107 Median 
PFS and OS rates in methylated patients were 8.9 and 14.2 months, respectively, versus 2.7 and 
9.2 months in unmethylated patients (P ≤ 0.031 for both end points). Notably, this small study 
also found that MGMT status did not appear to change between primary and recurrent tumors. 
In contrast, several other studies describe the absence of significant PFS and OS 
differences with regard to the methylation status of the MGMT promoter in patients with 
recurrent disease.43,47,52,84,108 In most of these studies, MGMT promoter methylation status was 
analyzed using MSP. The absence of a correlation between MGMT promotor status and positive 
outcome in these studies may be attributed to the overall poor prognosis at glioblastoma 
recurrence, a small sample size, or the lack of a true association between MGMT status and 
outcome at time of recurrence. In the RESCUE study, 50/120 patients had tissue available for 
MGMT analysis and 42% were methylated. The use of a continuous daily temozolomide regimen 
at first recurrence in the glioblastoma groups was associated with similar PFS at 6 months, time 
to progression, and OS in both methylated and unmethylated patients.51 It is unclear if the 
absence of correlation in this trial relates to the clinical factors listed previously or may be in part 
an effect of MGMT depletion with the protracted treatment schedule. Further validation studies 
in larger patient populations are needed to confirm that MGMT status is useful in predicting 
response to therapy and prognosis in patients with recurrent/progressive disease. The 
DIRECTOR trial57 will provide prospective data that may clarify this issue. Yet, the impact of 
MGMT status, if any, is likely to be small and in the range of a few months, as can be estimated 
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from the studies that reported any effect at all. 
 
Standard of care recommendations for recurrent/progressive glioblastoma 
Appropriate management outside of clinical trials requires individualization based on patient age, 
performance status, histology, extent of initial resection, type of and response to initial therapy, 
time since diagnosis, and whether the recurrence is local or diffuse.109 Repeat surgery, 
reirradiation, and second-line mono- or combination therapy are all primarily directed at 
reducing tumor burden and extension. All therapies aim to improve neurologic symptoms, e.g., 
headaches or seizures, reduce the need for certain medications or lower total daily doses, e.g., 
corticosteroids or antiepileptic drugs, and prevent thromboembolic complications. 
Predicting response to subsequent therapy in patients with recurrent disease remains difficult 
because of the biological complexity of glioblastoma110 as well as numerous other patient-
specific factors. The role of MGMT as a prognostic or predictive marker following relapse 
remains ambiguous. Most contemporary clinical trials include a translational research program, 
but no biomarkers of practical use have yet been established.111 
The 6-month PFS rate and median OS remain the most useful and accessible end points 
for monitoring outcomes following chemotherapy. OS is commonly considered the “gold 
standard” end point because it can be measured objectively and has clinical significance.112 
However, interpretation of OS can be affected by subsequent salvage therapy. PFS relies on a 
standardized method that defines tumor progression, but its determination can be challenging.15 
Currently the use of both median OS and 6-month PFS remain the best end points available for 
assessing therapeutic outcome in patients with recurrent disease. However, earlier PFS 
assessments also have been shown to similarly predict survival time and may become new end 
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points in future clinical trials.22  
Despite advanced imaging techniques, detecting tumor progression remains a clinical 
challenge in patients with glioblastoma because of the complexities of pseudoprogression and 
radionecrosis.113 An international expert panel has recently recommended that PFS should be 
correlated with OS end points and ideally validated with the RANO criteria.112 
 
Which patients are most likely to benefit from dose-dense (metronomic) temozolomide 
therapy? The theoretical benefit of the metronomic approach is that it may deplete MGMT, 
leading to restoration of temozolomide sensitivity in MGMT-methylated tumors and/or may limit 
endothelial cell recovery and upregulate thrombospondin 1, leading to a sustained antiangiogenic 
effect.109,114 Two randomized trials, the RTOG 0525 trial for newly diagnosed patients6 and the 
BR12 trial for recurrent malignant glioma patients,55 failed to demonstrate superiority of dose-
intensified temozolomide over conventional temozolomide. Yet, neither of these trials can 
answer the question whether dose-intensified temozolomide is a suitable option for patients 
failing standard temozolomide because this setting was not examined in either trial. Many dose-
dense rechallenge schedules have been evaluated as discussed above, e.g., 7/14 days, 21/28 days, 
6/8 weeks, or continuously daily. The RESCUE study provides a glimpse of possible 
subpopulations that might benefit the most from metronomic temozolomide therapy. Patients 
who progressed after concomitant temozolomide/radiotherapy during the 6-month course of 
adjuvant temozolomide as well as patients who progressed later than 2 months after completing 
adjuvant temozolomide therapy appeared to benefit more from continuous temozolomide therapy 
(50 mg/m2/d for 1 year) when compared with those who progressed while undergoing an 
extended adjuvant treatment of >6 months.51 Larger trials with prospective stratification of 
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patients by extent of prior temozolomide therapy would be needed to fully answer the question 
which patients are best treated by temozolomide rechallenge. 
Which temozolomide schedule provides the best outcome? Despite the increased number of 
prospective clinical trials conducted over the past 5 years, available data suggest that 6-month 
PFS and OS outcomes are similar among the various extended temozolomide dose-dense 
regimens used in patients with recurrent disease. However, most studies were small phase 2 trials 
and often included heterogeneous populations, e.g., varying types of prior chemotherapy, number 
of previous relapses, making it difficult to truly compare dose-dense regimens within or between 
trials. It may all come down to physician/patient preference and convenience unless the 
DIRECTOR trial57 generates a clear signal for 1 of the 2 evaluated regimens. 
Which temozolomide regimen has the least toxicity and is the best tolerated? In general, dose-
dense temozolomide is associated with manageable toxicity in patients with recurrent 
glioblastoma previously treated with temozolomide. Wick and colleagues reported that among 
the various dose-dense schedules tested in phase 2 trials, each had a similar distribution of grade 
1 to 4 toxicities.54 However, compared with standard 5-of-28-day regimen, dose-dense regimens 
are associated with an increased incidence and severity of lymphocytopenia.114 Available data 
from phase 2 trials suggests that lymphopenia occurs at a greater rate for patients receiving the 
“3-weeks-on, 1-week-off” regimen compared with the standard regimen. In general, at 
recurrence, starting at a moderate rechallenge dose may be advisable to identify the individual 
tolerance of the patients. 
Which combination chemotherapies make the most sense? Currently, no single combination 
regimen has clearly emerged as a “favorite” for the treatment of recurrent or progressive 
glioblastoma. Temozolomide, in combination with cisplatin, fotemustine, interferon, sorafenib, 
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celecoxib, irinotecan, or procarbazine, lomustine, and vincristine, has not been demonstrated to 
be more effective than temozolomide alone (Table 5). Similarly, various bevacizumab-based 
combinations were not superior to historical data obtained with bevacizumab alone (Table 6). 
Several other small studies have investigated the combination of protracted daily 
temozolomide (50 mg/m2/d for 2-3 weeks) and biweekly bevacizumab for recurrent disease.70,71 
This combination provided similar efficacy compared with either agent alone, although 
heterogeneous patient populations, e.g., inclusion of patients who both responded and failed 
upfront therapy, may have confounded the findings. 
 
Conclusions 
A plethora of monotherapy and combination chemotherapy strategies have been evaluated in 
patients with recurrent or progressive glioblastoma. Despite some minor improvements in PFS, 
no obvious increase in survival has been associated with any particular regimen. Future clinical 
trials, which adopt the revised Macdonald criteria (RANO), may provide new clues as to which 
agent or combination is most beneficial. Despite definitive data, standard of care guidance for 
managing patients with recurrent or progressive glioblastoma is evolving. Further insight 
regarding which patients should undergo a second resection or radiotherapy procedure, how to 
best use temozolomide and bevacizumab therapy, and the value of MGMT status assessment in 
the recurrent setting is forthcoming. 
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Table 1. Neuroimaging and Glioblastoma: Macdonald vs RANO Criteria 
 Macdonald RANO 
CR  Requires all of the following: 
 Complete disappearance of all 
enhancing measurable and 
nonmeasurable disease sustained for 
at least 4 weeks 
 No new lesions 
 No corticosteroids 
 Stable or improved clinically 
Requires all of the following: 
 Disappearance of all enhancing 
measurable and nonmeasurable 
disease sustained for a minimum of 4 
weeks 
 Stable or improved FLAIR/T2 lesions 
 No new lesions 
 Stable or improved clinically 
 Patients cannot be receiving 
corticosteroids (physiologic 
replacement doses are acceptable) 
PR Requires all of the following: 
 ≥50% decrease compared with 
baseline in the sum of products of 
perpendicular diameters of all 
measurable enhancing lesions 
sustained for at least 4 weeks 
 No new lesions 
 Stable or reduced corticosteroid dose 
 Stable or improved clinically 
Requires all of the following: 
 50% or greater decrease (compared 
with baseline) in the sum of products 
of perpendicular diameters of all 
measurable enhancing lesions 
sustained for a minimum of 4 weeks 
 No progression of nonmeasurable 
disease 
 No new lesions 
 Stable or improved FLAIR/T2 lesions 
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 Stable or improved clinically 
 Corticosteroid dosage at the time of 
the scan should be no greater than the 
dosage at the time of the baseline 
scan 
SD  Requires all of the following: 
 Does not qualify for CR, PR, or PD 
 Stable clinically 
Requires all of the following: 
 Patient does not qualify for CR, PR, 
or progression 
 Stable FLAIR/T2 lesions on a 
corticosteroid dose no greater than at 
baseline 
 Stable clinically 
PD  Defined by any of the following: 
 ≥25% increase in sum of the products 
of perpendicular diameters of 
enhancing lesions relative to best 
previous scan 
 Any new lesion 
 Clinical deterioration 
Defined by any of the following: 
 25% or greater increase in sum of the 
products of perpendicular diameters 
of all measurable enhancing lesions 
compared with the smallest tumor 
measurement obtained either at 
baseline or best response following 
the initiation of therapy, while on a 
stable or increasing dose of 
corticosteroids 
 Significant increase in FLAIR/T2 
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lesions compared with baseline or 
best response following initiation of 
therapy, not caused by comorbid 
events (eg, radiation therapy, 
ischemic injury, seizures, 
postoperative changes, or other 
treatment effects), while on a stable 
or increasing dose of corticosteroids 
 New lesions 
 Clinical deterioration not attributable 
to other causes apart from the tumor 
(eg, seizures, medication side effects, 
complications of therapy, 
cerebrovascular events, infection) or 
decreases in corticosteroid dose 
 Failure to return for evaluation due to 
death or deteriorating condition 
 Clear progression of nonmeasurable 
disease 
Abbreviations: CR, complete response; FLAIR, fluid-attenuated inversion recovery; PD, 
progressive disease; PR, partial response; RANO, Response Assessment in Neuro-Oncology; 
SD, stable disease. (Adapted from Lutz and Wen et al.)14,15 
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Table 2. Nitrosourea Trials in Recurrent or Progressive Glioblastomaa 
Reference 
Study 
Design/ 
Population 
TMZ  
Pre-
treatment 
Nitrosourea 
Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPFS* 
(mo) 
mOS* 
(mo) 
WHO Grade 3/4 
Toxicities (n) 
Monotherapy 
Van den 
Bent MJ  
et al25 
Phase 2, 
randomized 
 
Median age: 
54 y 
Some (not 
clearly 
specified) 
BCNU 60 mg/m2 
on days 1-3 q8wk 
for max 5 cycles. 
 
or 
TMZ 200 mg/m2 
on days 1-5 q4wk 
in chemotherapy-
naïve pts or 150 
mg/m2 on days 1-5 
q4wk after prior 
adjuvant 
chemotherapy, 
with dose 
escalation to 200 
mg/m2 in absence 
of significant 
toxicity (only 
combined data 
[Cntrl] for BCNU 
and TMZ 
reported) 
 
or 
ERL 150 mg/d, 
with dose 
BCNU: 
29 
 
 
 
TMZ: 
27 
 
 
(52 
eval-
uable in 
Cntrl) 
 
 
 
 
 
 
 
 
 
 
 
ERL: 
54 
CR: 0 
PR:  
Cntrl: 5  
vs ERL: 
2 
SD: 
Cntrl:18 
vs ERL: 
9 
 
Cntrl: 
24.1 
vs  
ERL: 
11.4 
Cntrl: 
2.4  
vs 
ERL 
1.8 
Cntrl: 
7.3 
vs 
ERL 
7.7 
Hematologic: 
BCNU: 13 
TMZ: 4 
ERL: 1 
 
Nonhematologic: 
BCNU: 8 
TMZ: 4 
ERL: 11 
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Reference 
Study 
Design/ 
Population 
TMZ  
Pre-
treatment 
Nitrosourea 
Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPFS* 
(mo) 
mOS* 
(mo) 
WHO Grade 3/4 
Toxicities (n) 
escalation to 200 
mg/d if no toxicity 
Brandes 
AA et al26  
Phase 2 
 
Median age: 
49.7 y; 
Median KPS: 
70 
No BCNU 80 mg/m2 
on days 1-3 q8wk 
for max 6 cycles 
40 CR: 0 
PR: 6 
SD: 9 
PD: NA  
17.5 
 
NA 7.53 Hematologic:  
NA 
Nonhematologic: 
9 
  
Reithmeier 
T et al27  
Retrospective 
analysis 
 
Median age: 
53 y; 
Median KPS: 
70; 
1st relapse: 
n=30; 
2nd relapse: 
n=4; 
4th relapse: 
n=1 
24 (69%) BCNU 80 mg/m2 
IV on days 1-3 
q8wk for max 6 
cycles 
35 CR: 0 
PR: 2 
SD: 19 
PD: 11 
13 
 
2.6 5.1 Hematologic:  
10 
Nonhematologic: 
4  
 
Wick W et 
al28  
Phase 3 open-
label,  
randomized 
2:1 
 
1st relapse: 
CCNU n=70; 
Enzastaurin 
NA CCNU 100-130 
mg/m2 on day 1 
q6wk 
 
 
Enzastaurin 500 
mg PO daily 
(1125-mg loading 
92 
 
 
 
 
174 
CR: 0 
PR: 4 
SD: 33 
PD: 38 
 
CR: 0 
PR: 5 
SD: 67 
19.0 
 
 
11.1 
1.6 
 
 
1.5 
7.1 
 
 
6.1 
Hematologic:  
46 
Nonhematologic: 
3 
 
Hematologic:  
1 
Nonhematologic: 
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Reference 
Study 
Design/ 
Population 
TMZ  
Pre-
treatment 
Nitrosourea 
Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPFS* 
(mo) 
mOS* 
(mo) 
WHO Grade 3/4 
Toxicities (n) 
n=129 
 
2nd relapse: 
CCNU n=21; 
Enzastaurin 
n=45 
dose on day 1) PD: 72 13 
 
(P < 0.007 for 
hematologic 
toxicities) 
 
Ahluwalia 
MS et al29 
Batchelor 
TT et al30 
Phase 3, 
multicenter, 
double-blind, 
randomized 
1:2:2 
 
Median age: 
54 y 
Yes CCNU 110 mg/m2 
q6wk + placebo  
 
 
or 
CED 30 mg/d 
 
 
 
or 
CED 20 mg/d + 
CCNU 110 mg/m2 
q6wk 
65 
 
 
 
 
131 
 
 
 
 
129 
CR: 0 
PR: 5 
SD: 23 
PD: 23 
 
CR: 1 
PR: 17 
SD: 76 
PD: 10 
 
CR: 2 
PR: 19 
SD: 67 
PD: 19 
24.5 
 
 
 
 
16 
 
 
 
 
34.5 
2.73 
 
 
 
 
3.1 
 
 
 
 
4.2 
9.8 
 
 
 
 
8.0 
 
 
 
 
9.4 
Hematologic:  
30 
Nonhematologic: 
16 
 
Hematologic:  
7 
Nonhematologic: 
66 
 
Hematologic:  
116 
Nonhematologic: 
57 
 
Happold, 
CJ et al31  
Retrospective 
analysis 2003-
2008, after 
failed therapy 
with TMZ or 
recurrence 
 
Yes ACNU 72-90 
mg/m2/d IV in 6-
wk cycles, 
alone or in 
combination 
14 
alone 
 
or 
18 in 
com-
binatio
n 
CR: 0b 
PR: 2b 
SD: 5b 
PD: NAb 
20b 2.7b 6.7b Hematologic:  
16b 
Nonhematologic: 
3b 
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Reference 
Study 
Design/ 
Population 
TMZ  
Pre-
treatment 
Nitrosourea 
Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPFS* 
(mo) 
mOS* 
(mo) 
WHO Grade 3/4 
Toxicities (n) 
 
Addeo R et 
al33 
Phase 2, 
multicenter, 
nonrandomize
d, single-arm 
 
Median age: 
52.8 y; 
Median KPS: 
90; 
1st relapse: 
100% 
Yes FOT IV 80 mg/m2 
on days 1, 15, 30, 
45, and 60 
(induction), then  
80 mg/m2 q4wk 
(maintenance) 
40 CR: 1 
PR: 9 
SD: 16 
PD: 14 
61 6.7 11.1  Hematologic: 
Induction: 5 
Maintenance: 5 
 
Nonhematologic: 
Induction: 0 
Maintenance: 3 
Brandes 
AA et al34 
Phase 2, non-
randomized, 
single-arm 
 
Median age: 
51 y; 
Median KPS: 
90 
Yes FOT 75-100 
mg/m2 for 3 
weekly doses 
followed, after a 5-
wk rest, by 100 
mg/m2 q3wk for 
≤1 yr 
43 CR: 0 
PR: 3 
SD: 15 
20.9 1.7 6.0 Hematologic: 
Induction  
(100 mg/m2): 24 
Amended 
induction  
(75 mg/m2): 19 
Maintenance: 8 
 
Nonhematologic: 
NA 
Scoccianti 
S et al35 
Phase 2, 
multicenter, 
single-arm 
 
Median age: 
56 y; 
Median KPS: 
Yes FOT IV 100 
mg/m2 qwk for 3 
consecutive wks 
(induction), then 
q3wk 
(maintenance) 
27 CR: 0 
PR: 8 
SD: 5 
PD: 14 
48.2 5.7 9.1 Hematologic:  
4 pts 
 
Nonhematologic: 
0  
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Reference 
Study 
Design/ 
Population 
TMZ  
Pre-
treatment 
Nitrosourea 
Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPFS* 
(mo) 
mOS* 
(mo) 
WHO Grade 3/4 
Toxicities (n) 
80; 
1st 
recurrence: 
100% 
Fabrini MG 
et al36  
Phase 2, 
multicenter, 
prospective, 
open-label, 
non-
comparative 
 
Median age: 
56.8 y; 
Median KPS: 
90 
Yes FOT 100 mg/m2 
IV on days 1, 8, 
and 15, followed 
by 4- to 6-wk rest 
period (induction). 
 
In nonprogressive 
pts, FOT 100 
mg/m2 IV q3wk 
(maintenance) 
50 CR: 1 
PR: 8 
SD: 22 
PD: 19 
52 6.1 8.1 Hematologic:  
7 pts 
 
Nonhematologic: 
0  
Combination Regimens 
Kappelle 
AC et al38 
Multicenter 
retrospective, 
1994-1998 
 
Median age: 
46 y; 
Median KPS: 
80 
Only 4 pts Standard or 
intensified PRO, 
CCNU, and VIN 
63 CR: 3 
PR: 8 
SD: 25 
29 NA 7.7 Hematologic:  
NA 
 
Nonhematologic: 
NA 
Schmidt F 
et al.37 
Retro-spective 
chart review, 
1994-2003 
 
Median age: 
Only 12 
pts 
PRO 60 mg/m2 PO 
days 8-21, CCNU 
110 mg/m2 PO day 
1, VIN 1.4 mg/m2 
[max 2 mg] IV 
86 CR: 0 
PR: 3 
SD: 45 
PD: 18 
38.4 4.0 7.8 Hematologic:  
30 pts 
 
Nonhematologic:
0 
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Reference 
Study 
Design/ 
Population 
TMZ  
Pre-
treatment 
Nitrosourea 
Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPFS* 
(mo) 
mOS* 
(mo) 
WHO Grade 3/4 
Toxicities (n) 
49 y; 
1st relapse: 
100% 
days 8 and 29; 
given in 8-wk 
cycles 
Abbreviations: ACNU, nimustine; BCNU, carmustine; CCNU, lomustine; CED, cediranib; Cntrl, control arm; CR, complete response; 
ERL, erlotinib; FOT, fotemustine; IV, intravenous; max, maximum; KPS, Karnofsky Performance Score; mOS, median overall 
survival; mPFS, median progression-free survival; NA, not available; PD, progressive disease; PFS, progression-free survival; PR, 
partial response; PRO, procarbazine; pts, patients; SD, stable disease; TMZ, temozolomide; VIN, vincristine. 
For the most part, only glioblastoma data are presented in the table. We have reported enrollment numbers for different patient 
populations only when all data in a paper are presented for combined patient populations. 
* The disease progression-free survival and the overall survival were calculated from beginning of retreatment. 
a All data presented for glioblastoma patients only. 
b Data for ACNU alone were not available; the numbers listed represent responses for all patients (ACNU alone and in combination). 
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Table 3. Temozolomide Monotherapy Trials in Recurrent or Progressive Glioblastomaa  
Ref 
Study 
Design/ 
Population 
TMZ 
Pretreat-
ment  
TMZ 
Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPFS* 
(mo) 
mOS* 
(mo) 
WH Grade 3/4 
Toxicities (n) 
Temozolomide-Naïve Population 
Brada M 
et al24 
Phase 2, 
open-label, 
uncontrolled 
TMZ at 1st 
relapse 
 
Median age: 
54 y; 
Median time 
to 1st relapse: 
8.1 mo 
No 
(40% of pts 
had prior 
nitrosourea-
containing 
chemo-
therapy) 
Chemotherap
y-naïve pts: 
200 mg/m2/d 
PO for 1st 5 
days of 28-
day cycle 
  
Pts with 
previous 
nitrosourea-
containing 
adjuvant 
chemotherapy
: 150 mg/m2/d 
for 1st 5 days 
of 28-day 
cycle 
126 CR: 2 
PR: 8 
SD: 57 
18 2.1 5.4 Hematologic: 
30 
Nonhematologic:
30 
Brandes 
AA et 
al39  
Phase 2 
2nd relapse 
No 
(previous 
PCV) 
150 mg/m2/d 
for 5 days 
q28d 
22 CR: 2 
PR: 3 
SD: 4 
31.8  7.6 Hematologic: 
4 
Nonhematologic:
2 
Brandes 
AA et 
al40  
Phase 2 
 
Mean age: 
48.4 y; 
Median KPS: 
80 
No 
(previous 
PCV) 
150 mg/m2/d 
for 5 days 
q28d 
42 CR: 2 
PR: 6 
SD: 9 
PD: NA 
24 NA 7.0 Hematologic: 
1  
Nonhematologic:
0  
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Ref 
Study 
Design/ 
Population 
TMZ 
Pretreat-
ment  
TMZ 
Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPFS* 
(mo) 
mOS* 
(mo) 
WH Grade 3/4 
Toxicities (n) 
2nd relapse 
Khan RB 
et al41  
Phase 2, 
prospective, 
extended low-
dose, single-
center 
No 75 mg/m2/d 
for 42 days 
q70d 
28 CR: 0 
PR: 0 
SD: 11 
PD: 17 
19 2.3 7.7 Hematologic: 
8 
Nonhematologic:
0 
Wick W 
et al46 
 
Phase 2, 
nonrandomize
d, prospective 
No 150 mg/m2 on 
days 1-7 and 
days 15-21 of 
28-day cycles 
for max 12 
cycles 
21 CR: 0 
PR: 2 
SD: 17 
PD: 2 
48 4.9 NA Hematologic: 
10 
Nonhematologic:
7 
Chan DT 
et al42  
Prospective, 
open-label, 
compassionat
e use in 
Chinese pts  
No 200 mg/m2/d 
for 5 days 
q28d for 4 
cycles 
13 NA 21.0 NA NA Hematologic: 
0 
Nonhematologic:
0 
Brandes 
AA et 
al43  
Phase 2  
 
Median age: 
57 y; 
Median KPS: 
90 
No 75 mg/m2/d 
for 21 days 
q28d 
33 CR: 1 
PR: 2 
SD: 17 
30.3 3.8 9.3 Hematologic: 
14 
Nonhematologic:
4 
Nagane 
M et al44  
Prospective, 
open-label 
 
Mean age: 
48.2 y; 
Median KPS: 
No 
(89.5% had 
previous 
nitrosourea-
based 
therapy) 
150-200 
mg/m2/d for 5 
days q28d 
19 CR: 1 
PR: 3 
SD: 6 
PD: 7 
22.2 2.2 9.9 Hematologic: 
5 
Nonhematologic:
9 
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Ref 
Study 
Design/ 
Population 
TMZ 
Pretreat-
ment  
TMZ 
Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPFS* 
(mo) 
mOS* 
(mo) 
WH Grade 3/4 
Toxicities (n) 
70 
Balmace
da C et 
al45  
Phase 2, 
single-arm, 
multicenter 
 
Median age: 
43 y; 
1st relapse: 
n=48; 
≥2 relapses: 
n=20 
No 
(previous 
non-
nitrosourea: 
n=7; 
nitrosourea: 
n=33; 
none: n=28) 
200 mg/m2 
initial dose, 
then 9 
consecutive 
doses at 90 
mg/m2 q12h 
for 28 days; 
increased to 
100 mg/m2 
q12h in 
absence of 
toxicity 
68 CR: 3 
PR: 18 
SD: 22 
PD: 19 
35 4.0 9.0 Hematologic: 
NA 
Nonhematologic:
NA 
Temozolomide-Pretreated Population 
Francesc
hi E et 
al48  
Retrospective 
analysis 
Yes 150-200 
mg/m2/d for 5 
days, q28d in 
13 pts, 25 
mg/m2/d 
continuously 
in 1 pt 
9 CR: 2 
PR: 2 
SD: 2 
PD: 3 
NA 7.0 12+ Hematologic: 
1 
Nonhematologic:
0 
Kong DS 
et al49  
Pilot study, 
metronomic 
  
Median age: 
48.3 y 
Yes 40 mg/m2/d (3 
mo) 
12 CR: 0 
PR: 2 
SD: 5 
PD: 5 
58.3 6.0 11 Hematologic: 
0 
Nonhematologic:
0 
Wick W 
et al47  
Prospective, 
non-
randomized: 
9/64 pts had 
received 
TMZ  
150 mg/m2 on 
days 1-7 and 
days 15-21 
64 NA 43.8 5.5 NA NA 
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Ref 
Study 
Design/ 
Population 
TMZ 
Pretreat-
ment  
TMZ 
Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPFS* 
(mo) 
mOS* 
(mo) 
WH Grade 3/4 
Toxicities (n) 
alternating 
weekly 
regimen 
Median age: 
51 y 
(+ CCNU) q28d (1-wk 
on, 1-wk off) 
Wick W 
et al54b 
 
 
Retrospective 
analysis, 3 
centers, 2000-
2007 
 
Median age: 
52 y 
 
2 cohorts: 
TMZ 
escalation 
with 
progression 
during TMZ 
vs  
TMZ 
rechallenge 
after stable 
disease and 
disease-free 
interval 
Yes 75 mg/m2/d 
(days 1-42 
during 
radiotherapy), 
plus 150-200 
mg/m2/d for 5 
days q28d 
 
or 
150-200 
mg/m2/d for 5 
days q28d 
 
or 
150 mg/m2/d 
for 1-wk on, 
1-wk off 
 
or 
75 mg/m2/d 
for 21 days 
q28d 
 
or 
47 NA 
 
27.7 
(pro-
gressive 
cohort 
26.3 vs  
stable 
cohort 
28.6%) 
 5.8 
(pro-
gressive 
cohort 
6.6 vs  
stable 
cohort 
5.3) 
Hematologic: 
22 
Nonhematologic:
10 
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Ref 
Study 
Design/ 
Population 
TMZ 
Pretreat-
ment  
TMZ 
Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPFS* 
(mo) 
mOS* 
(mo) 
WH Grade 3/4 
Toxicities (n) 
40 mg/d 
continuousc 
Berrocal 
A et al50  
Phase 2, 
multicenter  
Yes 85 mg/m2 for 
21 days q28d 
GB: 
27 
 
AA: 
15 
 
Misc
: 5 
CR: 0 
PR: 2 
SD: 15a 
PD: 30a 
0 
 
 
NA 5.1a NA 
 
Perry JR 
et al51 
Phase 2, 
continuous 
dose-intense 
(RESCUE 
study), 
multicenter 
 
Pts 
prospectively 
divided into 3 
groups (early, 
extended, and 
rechallenge) 
per timing of 
progression 
during 
adjuvant 
therapy 
Yes 50 mg/m2/d 
continuous 
for max 1 yr 
or progression 
91 NA 
 
23.9 
(early 
27.3; 
extended 
7.4; re-
challenge 
35.7) 
NA 
(early 
3.6; 
extended 
1.8; re-
challenge 
3.7) 
9.3 NA 
 
Kong DS Phase 2, low- Yes 40-50 38 CR: 0 32.5 4.0 9.6 Hematologic: 
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Ref 
Study 
Design/ 
Population 
TMZ 
Pretreat-
ment  
TMZ 
Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPFS* 
(mo) 
mOS* 
(mo) 
WH Grade 3/4 
Toxicities (n) 
et al52  dose, 
continuous 
(metronomic) 
 
Median age: 
51 y  
mg/m2/d PR: 2 
SD: 21 
4 
Nonhematologic:
0 
Hammon
d A et 
al53 
(prelim 
results 
only) 
Phase 2, dose-
intense, 
single-arm 
1st recurrence 
Median age: 
57 y; 
Median KPS: 
90 
Yes 75-100 
mg/m2/d for 
21 days q28d 
47 CR: 0  
PR: 6 
SD: 18 
23 2.3 13 Hematologic: 
7 
Nonhematologic:
NA 
Randomized Studies 
Yung 
WK et 
al23 
Phase 2, 
randomized, 
multicenter, 
open-label  
 
1st relapse: 
100%; 
Median age: 
51-52 y 
No 
(65-68% of 
pts received 
prior 
nitrosourea) 
TMZ 150-200 
mg/m2/d for 5 
days q28d  
 
or 
Procarbazine 
150 mg/m2/d 
(or 125 
mg/m2/d if 
prior chemo-
therapy) PO 
for 28 days, 
repeated q56d 
112 
 
 
 
 
113 
CR: 0 
PR: 6 
SD: 45 
 
 
CR: 0 
PR: 6 
SD: 31 
21 
 
 
 
 
8 
2.9 
 
 
 
 
1.9 
NA Hematologic: 
14 
Nonhematologic:
12 
 
Hematologic: 
9 
Nonhematologic:
17 
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Ref 
Study 
Design/ 
Population 
TMZ 
Pretreat-
ment  
TMZ 
Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPFS* 
(mo) 
mOS* 
(mo) 
WH Grade 3/4 
Toxicities (n) 
Brada M 
et al55 
Prospective, 
randomized 
  
1st 
progression: 
100% 
No  
(chemo-
therapy-
naïve) 
TMZ 200 
mg/m2 for 5 
days 
 
 
or 
TMZ 100 
mg/m2 for 21 
days 
 
 
or 
PCV 
GB: 
72 
AA: 
15 
 
 
GB: 
66 
AA: 
15 
 
 
GB: 
139 
AA: 
23 
NA 
 
NA 5.0a 
 
 
 
 
 
4.2a 
 
 
 
 
 
3.6a 
8.5a 
 
 
 
 
 
6.6a 
 
 
 
 
 
6.7a 
Hematologic: 
38a 
Nonhematologic:
37a 
 
 
Hematologic: 
28a 
Nonhematologic:
38a 
 
 
Hematologic: 
57a 
Nonhematologic:
64a 
Abbreviations: AA, anaplastic astrocytoma; CR, complete response; GB, glioblastoma; KPS, Karnofsky Performance Score; mOS, 
median overall survival; mPFS, median progression-free survival; PCV, procarbazine, CCNU, and vincristine; PD, progressive 
disease; PFS, progression-free survival; PR, partial response; pts, patients; SD, stable disease; TMZ, temozolomide.  
For the most part, only glioblastoma data are presented in the table. We have reported enrollment numbers for different patient 
populations only when all data in a paper are presented for combined patient populations. 
*The disease progression-free survival and the overall survival were calculated from beginning of retreatment with temozolomide.  
a Data presented for glioblastoma patients only except for Berrocal 2010 study,50 where 27 patients had glioblastoma, 15 had 
anaplastic astrocytoma, and 5 had miscellaneous brain tumors, and Brada 2010 study,55 where 277 patients had glioblastoma, 53 had 
anaplastic astrocytoma, and 20 had miscellaneous brain tumors. 
b Retrospective study. 
c 11patients also received 13-cis-retinoic acid or pegylated liposomal doxorubicin.
Standard of Care for Recurrent Glioblastoma Page 60 of 75  
Table 4. Bevacizumab Monotherapy and Miscellaneous Antiangiogenic Trials in Recurrent or Progressive Glioblastomaa 
Reference 
Study Design/ 
Population 
TMZ 
Pre-
treatment
Antiangiogenic 
Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPFS* 
(mo) 
mOS* 
(mo) 
WHO Grade 3/4 
Toxicities(n) 
Bevacizumab Monotherapy 
Friedman 
HS et al59  
Phase 2, 
multicenter, 
open-label 
 
1st relapse: 
n=69  
2nd relapse: 
n=16 
Yes 10 mg/kg IV q2wk 
(28-day cycle) 
85 CR: 1 
PR: 23 
42.6 
(1st 
relapse 
46.4 
vs  
2nd 
relapse 
27.8) 
4.2 
(1st 
relapse 
4.4 vs  
2nd 
relapse 
3.1) 
9.2 
(1st 
relapse 
9.1 vs 
2nd 
relapse 
9.2) 
Hematologic:  
3 
Nonhematologic:
36 
Kreisl TN et 
al60  
Phase 2  
 
1st recurrence; 
Median age: 53 
y; 
Median KPS: 
90 
Yes Initial 
monotherapy with 
10 mg/kg IV q2wk 
(28-day cycle)  
48 CR: 1 
PR: 16 
29 
 
3.7 7.2 Hematologic:  
1 
Nonhematologic:
12 
Raizer JJ et 
a.61  
Phase 2 Yes 15 mg/kg q3wk GB 
50 
 
NA 
 
25 
 
NA 6.5 NA  
Chamberlain 
MC et al62  
Retrospective 
review, 2005-
2008 
 
Pts aged 36-70 
y  
 
Salvage 
regimen: PCV: 
Yes 10 mg/kg IV q2wk 
(14-day cycle) 
(median 2 cycles 
received) 
50 CR: 0 
PR: 21 
SD: 0 
PD: 29 
42 10 8.5 Hematologic:  
1 
Nonhematologic:
11 
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Reference 
Study Design/ 
Population 
TMZ 
Pre-
treatment
Antiangiogenic 
Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPFS* 
(mo) 
mOS* 
(mo) 
WHO Grade 3/4 
Toxicities(n) 
n=21; 
CYC: n=13; 
n=13 underwent 
repeat surgery 
 
 
Miscellaneous Antiangiogenic Therapies 
Ahluwalia 
MS et al 29  
 
Batchelor 
TT et al30 
Phase 3, 
multicenter, 
double-blind, 
randomized 
1:2:2 
 
Median age: 54 
y 
Yes CCNU 110 mg/m2 
q6wk + placebo  
 
 
or 
CED 30 mg/d 
 
 
 
or 
CED 20 mg/d + 
CCNU 110 mg/m2 
q6wk 
65 
 
 
 
 
131 
 
 
 
 
129 
CR: 0 
PR: 5 
SD: 23 
PD: 23 
 
CR: 1 
PR: 17 
SD: 76 
PD: 10 
 
CR: 2 
PR: 19 
SD: 67 
PD: 19 
24.5 
 
 
 
 
16 
 
 
 
 
34.5 
2.73 
 
 
 
 
3.1 
 
 
 
 
4.2 
9.8 
 
 
 
 
8.0 
 
 
 
 
9.4 
Hematologic:  
30 
Nonhematologic:
16 
 
Hematologic:  
7 
Nonhematologic:
66 
 
Hematologic:  
116 
Nonhematologic:
57 
de Groot JF 
et al65  
Phase 2, single-
arm, 2007-2008 
 
1st relapse; 
Median age: 55 
y; 
Median KPS: 
90 
Yes Aflibercept (VEGF 
trap) 4 mg/kg IV 
on day 1 of q2wk 
cycle 
42 CR: 0 
PR: 7 
SD: NA 
PD: NA 
7.7 2.8 9.1 NA 
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Reference 
Study Design/ 
Population 
TMZ 
Pre-
treatment
Antiangiogenic 
Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPFS* 
(mo) 
mOS* 
(mo) 
WHO Grade 3/4 
Toxicities(n) 
Wen PY et 
al67,115  
Phase 2 
randomized 
 
Median age: 55 
y; 
34% received 
prior 
antiangiogenic 
therapy; 
2nd relapse: 
34% 
NA XL184  
125 mg PO 
 
or 
175 mg  
qd 
78 
 
 
 
46 
NA >25 
 
 
 
21 
NA NA NA 
Reardon DA 
et al68  
Phase 2 
randomized,  
2004-2005 
 
≤1 prior 
chemotherapy 
regimen; 
Median age: 52 
y; 
1st recurrence: 
100% 
Yes 
(99%) 
CIL 500 mg 
 
 
 
 
or 2000 mg, 
  
2/wk on a 
continuous basis 
41a 
 
 
 
 
40a 
CR: 0a 
PR: 2a 
SD: NA 
PD: NA 
 
CR: 0a 
PR: 5a 
SD: NA 
PD: NA 
10a 
 
 
 
 
15a 
NA 6.5a 
 
9.9a 
Hematologic:  
5a 
Nonhematologic:
2a 
 
Hematologic:  
3a 
Nonhematologic:
2a 
Gilbert MR 
et al69  
Phase 2, single-
agent, 
randomized 
 
Progressive 
disease 
following 
NA CIL IV 500 or 
2000 mg  3 doses 
(on days -8, -4, and 
-1), followed by 
resection, then 
2000 mg 2/wk  
26 NA 12 1.9 NA Hematologic:  
8 
Nonhematologic:
1 
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Reference 
Study Design/ 
Population 
TMZ 
Pre-
treatment
Antiangiogenic 
Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPFS* 
(mo) 
mOS* 
(mo) 
WHO Grade 3/4 
Toxicities(n) 
radiotherapy; 
Median age: 54 
y 
Abbreviations: CCNU, lomustine; CED, cediranib; CIL, cilengitide; CR, complete response; CYC, cyclophosphamide; GB, 
glioblastoma; IV, intravenous; KFS, Karnofsky Performance Score; mOS, median overall survival; mPFS, median progression-free 
survival; NA, not available; PCV, procarbazine, CCNU, and vincristine; PD, progressive disease; PFS, progression-free survival; PR, 
partial response; pts, patients; SD, stable disease, TMZ, temozolomide. 
For the most part, only glioblastoma data are presented in the table. We have reported enrollment numbers for different patient 
populations only when all data in a paper are presented for combined patient populations. 
*The disease progression-free survival and the overall survival were calculated from beginning of retreatment. 
a Data presented for glioblastoma patients only, except for Reardon 2008,68 where 6 patients had either anaplastic astrocytoma or low-
grade glioma. 
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Table 5. Temozolomide-Containing Combination Trials in Recurrent or Progressive Glioblastomaa 
 
Reference 
Study Design/ 
Population 
TMZ 
Pretreat-
ment Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPFS* 
(mo) 
mOS* 
(mo) 
WHO Grade 3/4 
Toxicities (n) 
Temozolomide + Bevacizumab Combinations
Desjardins et 
al85  
Phase 2 
 
Median age: 56 
y 
 
1st progression: 
n=15 
2nd progression: 
n=15 
3rd progression: 
n=2 
Yes 
(prior 
BEV 4 
pts) 
TMZ 50 
mg/m2/d + 
BEV 10 mg/kg 
IV q2wk 
32 CR: 0 
PR: 9 
SD: 16 
PD: 7 
18.8 3.7 8.7 Hematologic: 
0 
Nonhematologic: 
11 (including 1 
grade 5 infection) 
Verhoeff JJ 
et al70  
Phase 1/2 
 
Median age: 55 
y 
Yes TMZ 50 
mg/m2/d q3wk  
+ 
BEV 10 mg/kg 
IV q3wk 
15 NA 6.7  2.4 3.7 NA 
Temozolomide + Nitrosourea Combinations
Gaviani P et 
al73  
Noncomparative, 
single-arm 
Yes TMZ 150 
mg/m2 on days 
1-7 and 15-21 of 
28-day cycles  
+ 
FOT single IV 
infusion 110 
mg/m2 monthly 
on day 15 
20 
(only 
10 
eval-
uable)
NA 40 4.3 NA Hematologic: 
Severe 
Nonhematologic: 
NA 
Temozolomide + Interferon Combinations
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Reference 
Study Design/ 
Population 
TMZ 
Pretreat-
ment Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPFS* 
(mo) 
mOS* 
(mo) 
WHO Grade 3/4 
Toxicities (n) 
Groves MD 
et al74  
Two phase 2 
noncomparative 
studies 
 
Short-acting 
IFN: 
Median age: 55 
y 
Median KPS: 80 
 
PEG-IFN: 
Median age: 56 
y 
Median KPS: 90 
No TMZ 150-200 
mg/m2/d for 5 
days every 
month + 
Short-acting 
IFN-α2b: 4 MU/ 
m2 SC 3x/wk 
 
and 
 
TMZ 150-200 
mg/m2/d  5 
days every 
month  
+ 
Long-acting 
PEG-IFN-α2b 
SC 0.5 
µg/kg/wk 
29 
 
 
 
 
 
 
 
 
 
26 
CR: 0 
PR: 4 
SD: 18 
 
 
 
 
 
 
 
CR: 0 
PR: 1 
SD: 17 
 
31 
 
 
 
 
 
 
 
 
 
38 
3.6 
 
 
 
 
 
 
 
 
 
4.4 
7.2 
 
 
 
 
 
 
 
 
 
10.0 
Hematologic: 
18 
Nonhematologic: 
10 
 
 
 
 
 
 
Hematologic: 
17 
Nonhematologic: 
23 
Temozolomide + Miscellaneous Chemotherapy Combinations
Reardon DA 
et al75  
Phase 2, single-
arm 
 
Median age: 
53.6 y 
Yes TMZ continuous 
daily 50 
mg/m²/d  + 
Sorafenib 400 
mg 2/d  
32 CR: 0 
PR: 1 
SD: 15 
PD: 16 
9.4 1.5 9.7 Hematologic: 
1 
Nonhematologic: 
27 
Eisenstat DD 
et al82  
 
Phase 2 
 
Median age: 58 
y 
Yes 
(prior 
chemo-
radio-
TMZ 75 mg/m2 
for 21 days per 
28-day cycle  
+ 
39 
 
 
 
CR: 1 
PR: 2 
SD: 14 
PD: 17 
10 
 
 
 
1.5 
 
 
 
NA 
 
Hematologic: 
0 
Nonhematologic: 
11 
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Reference 
Study Design/ 
Population 
TMZ 
Pretreat-
ment Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPFS* 
(mo) 
mOS* 
(mo) 
WHO Grade 3/4 
Toxicities (n) 
 
1st recurrence: 
100% 
 
therapy) Afatinib 40 
mg/d 
  
or 
Afatinib 40 
mg/d 
 
 
 
or 
TMZ 75 mg/m2 
for 21 days per 
28-day cycle 
 
 
 
 
41 
 
 
 
 
 
39 
 
 
 
 
CR: 0 
PR: 1 
SD: 14 
PD: 23 
 
 
CR: 0 
PR: 4 
SD: 21 
PD: 13 
 
 
 
 
3 
 
 
 
 
 
23 
 
 
 
 
1.0 
 
 
 
 
 
1.9 
 
 
 
 
Hematologic: 
5 
Nonhematologic: 
10 
 
Hematologic: 
3 
Nonhematologic: 
17 
Quinn JA et 
al83  
Phase 2, open-
label 
Yes TMZ 472 
mg/m2 PO on 
day 1 of 28-day 
cycle  
+ 
O(6)-BG 1-h 
infusion of 120 
mg/m2, followed 
immediately by 
a 48-h infusion 
of 30 mg/m2 on 
day 1 of 28-day 
cycle 
34 CR: 0 or 1 
PR: 0 or 1 
SD: NA 
PD: NA 
9 1.8 4.5 NAb 
Stockhammer 
F et al84  
Retrospective 
analysis 
Yes  
(except 4 
TMZ 10 mg/m2 
bid  
28 CR: 0 
PR: 3 
43 4.2 16.8 Hematologic: 
1 
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Reference 
Study Design/ 
Population 
TMZ 
Pretreat-
ment Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPFS* 
(mo) 
mOS* 
(mo) 
WHO Grade 3/4 
Toxicities (n) 
 
1st recurrence: 
n=24; 
2nd recurrence: 
n=4 
pts) +  
CEL 200 mg/d 
SD: 15 
PD: 10 
Nonhematologic: 
NA 
Boiardi A et 
al76  
Nonrandomized, 
retrospective 
 
 
 
No TMZ 200 
mg/m2 days 1-5 
every 28 days  
+  
Resection 
+  
mitoxantrone, 
delivered 
through Rickam 
reservoir (4 
mg/d on days 1-
5 q28d) 
 
or 
TMZ + 
resection 
 
or 
TMZ 200 
mg/m2 days 1-5 
q28d alone 
65 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 
 
 
 
161 
NA 70.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
64 
 
 
 
39.3 
NA 11 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
 
 
 
5 
NA 
Reardon DA 
et al77  
Phase 1 No TMZ 200 
mg/m2/d days 1-
5 + 
91 NAb 27.3 12.8 NAb NAb 
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Reference 
Study Design/ 
Population 
TMZ 
Pretreat-
ment Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPFS* 
(mo) 
mOS* 
(mo) 
WHO Grade 3/4 
Toxicities (n) 
CPT-11 40 
mg/m2 to 375 
mg/m2 IV on 
weeks 1, 2, 4, 
and 5 of each 6-
wk cycle 
Chua SL et 
al78  
Phase 2, open-
label 
 
Median age: 55 
y 
1st relapse 
No  
(prior 
chemo-
therapy: 
9%) 
TMZ 200 
mg/m2 PO on 
days 1-5 q4wk + 
Liposomal DOX 
40 mg/m2 IV on 
day 1 q4wk 
22 CR: 1 
PR: 3 
SD: 11 
PD: 7 
32 3.6 8.2 Hematologic: 
8 
Nonhematologic: 
9 
Silvani A et 
al79  
Phase 2, single-
center 
 
Median time 
from 1st 
diagnosis: 8 mo 
No TMZ 200 
mg/m2 on days 
2-6 q4wk  
+ 
CIS 40 mg/m2, 
on days 1 and 2 
q4wk 
20 CR: 0 
PR: 2 
SD: NA 
PD: NA 
35 NA NAb NAb 
Brandes AA 
et al80  
Phase 2, 
multicenter  
 
Median age: 
53.4 y 
Median KPS: 80 
No  
(chemo-
therapy-
naïve) 
TMZ 130 
mg/m2 bolus 
followed by 9 
doses of 70 
mg/m2 q12h 
(total of 5 days) 
from day 2 
q4wk (if no 
hematologic 
toxicity dose, 
50 CR: 1 
PR: 9 
SD: NA 
PD: NA 
34 4.3 11.2 Hematologic: 
13 
Nonhematologic: 
4 
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Reference 
Study Design/ 
Population 
TMZ 
Pretreat-
ment Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPFS* 
(mo) 
mOS* 
(mo) 
WHO Grade 3/4 
Toxicities (n) 
increased to 100 
mg/m2)  
+ 
CIS 75 mg/m2 
on day 1 q4wk 
Abbreviations: BEV, bevacizumab; CEL, celecoxib; CIS, cisplatin; CPT-11, irinotecan; CR, complete response; DOX, doxorubicin; 
FOT, fotemustine; IFN, interferon; IV, intravenous; KPS, Karnofsky Performance Score; mOS, overall survival; mPFS, median 
progression-free survival; NA, not available; O(6)-BG, O(6)-benzylguanine; PD, progressive disease; PEG-IFN, PEGylated 
interferon; PFS, progression-free survival; PR, partial response; SC, subcutaneous; SD, stable disease; TMZ, temozolomide. 
For the most part, only glioblastoma data are presented in the table. We have reported enrollment numbers for different patient 
populations only when all data in a paper are presented for combined patient populations. 
*The disease progression-free survival and the overall survival were calculated from beginning of retreatment with temozolomide. 
a Data presented for glioblastoma patients only. 
b Data not available because not presented separately for glioblastoma and other glioma patients
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Table 6. Bevacizumab-Containing Combination Trials (Other Than Temozolomide) in Recurrent or Progressive Gioblastomaa 
Reference 
Study Design/ 
Population 
TMZ 
Pretreat-
ment  
Bevacizumab 
Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPF
S* 
(mo) 
mOS
* 
(mo) 
WHO Grade 3/4 
Toxicities (n) 
Bevacizumab + Temozolomide Combinations
Bevacizumab + Miscellaneous Chemotherapy Combinations 
Francesconi 
AB et al86  
Retrospective 
single-center 
review 
Yes BEV 10 mg/kg IV 
on day 2  
+ 
CP IV on day 1  
+ 
ETO phosphate 
113.6 mg/m2 
(equivalent to ETO 
100 mg/m2) IV, 
days 1-3 
Treatment repeated 
q3wk 
6 CR: NA 
PR: 5 
SD: NA 
PD: NA 
22 4.4 7.0 Hematologic: 
2 
Nonhematologic:
NA 
Hasselbalch 
B et al87  
Phase 2 
 
Recurrent 
primary 
(within 6 mo 
of standard 
TMZ 
concomitant 
and adjuvant 
therapy) 
Yes BEV 5 mg/kg first 
10 pts, then 10 
mg/kg IV q2wk  
+ 
CPT-11 340 mg/m2 
IV if receiving 
EIAED or if 
not,125 mg/m2 
q2wk 
+ 
CET 400 mg/m2 IV 
as loading dose, 
followed by 250 
mg/m2/wk  
43  
(32 
eval-
uable) 
CR: 2 
PR: 9 
SD: 17 
PD: 4 
33  3.7 7.0 Hematologic: 
4  
Nonhematologic:
20  
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Reference 
Study Design/ 
Population 
TMZ 
Pretreat-
ment  
Bevacizumab 
Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPF
S* 
(mo) 
mOS
* 
(mo) 
WHO Grade 3/4 
Toxicities (n) 
Sathornsum
etee S et al90 
Phase 2, open-
label 
 
Median age: 
52.4 y; 
1st relapse: 
52%; 
2nd relapse: 
36%; 
3rd relapse: 
12% 
Yes BEV IV 10 mg/kg 
IV q2wk  
+ 
ERL 500 mg/kg/d 
IV if receiving 
EIAED or, if not, 
200 mg/kg/d (42-
day cycle) 
25  
(24 
eval-
uable) 
CR: 1 
PR: 11 
SD: 10 
PD: 2 
29.2 4.2 10.3 Hematologic: 
4 
Nonhematologic:
64  
Gilbert MR 
et al96  
Phase 2: 
RTOG 0625 
 
Median age: 
57 y; 
Median KPS: 
80 
Yes BEV 10 mg/kg  
+ 
CPT-11 200 mg/m2 
q2wk 
57 CR: NA 
PR: NA 
SD: NA 
PD: NA 
37 NA NA Hematologic: 
14 
Nonhematologic:
NA 
Nghiemphu 
PL et al89  
Retrospective 
chart review, 
Jul 2005-Jul 
2006, single-
center 
 
BEV cohort: 
Median age 55 
y; 
Median KPS 
90; 
Yes BEV 5 mg/kg 
q2wk 
+ 
Chemotherapy: 
CPT-11: 31  
CP: 8  
CCNU: 3  
ETO: 2  
 
[Dosages not 
provided] 
Chemo
therap
y w/ 
BEV: 
44 
 
vs  
 
Chemo
therap
y w/o 
NA 41 
 
 
 
 
 
vs 
 
18 
4.25 
 
 
 
 
 
vs 
 
1.82 
9.0 
 
 
 
 
 
vs 
 
6.1 
NA 
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Reference 
Study Design/ 
Population 
TMZ 
Pretreat-
ment  
Bevacizumab 
Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPF
S* 
(mo) 
mOS
* 
(mo) 
WHO Grade 3/4 
Toxicities (n) 
1st relapse: 
50%; 
2nd relapse: 
32%; 
3rd relapse: 
18% 
BEV: 
79 
Friedman 
HS et al59  
Phase 2, 
multicenter, 
open-label 
 
Median age: 
57 y; 
1st relapse: 
80%; 
2nd relapse: 
20% 
Yes BEV 10 mg/kg IV 
q2wk 
+ 
CPT-11 340 mg/m2 
IV if receiving 
EIAED or if not, 
125 mg/m2, q2wk 
82 CR: 2 
PR: 29 
SD: NA 
PD: NA 
50.3 
(1st 
relapse: 
49; 
 
2nd 
relapse:
57.1) 
5.6 8.7 Hematologic: 
20 
Nonhematologic:
62 
Narayana A 
et al88  
Prospective, 
consecutive 
analysis, 2005-
2007 
Yes 
(except 1 
pt) 
BEV IV 10 mg/kg 
q2wk for 4 doses in 
8-wk cycle  
+ 
CPT-11 125 
mg/m2/d q2w or 
CP (dose to 
achieve an AUC = 
6 q4wk 
GB: 37 
AA: 24
CR: 7a 
PR: 32a 
SD: 11a 
PD: 3a 
44.3a 5.0a 9.0a NA 
Vredenburg
h JJ et al94  
Phase 2 Yes BEV 10 mg/kg IV 
q2wk 
+ 
CPT-11 340 mg/m2 
23 CR: 1 
PR: 13 
SD: 8 
PD: 1 
30 4.7 9.3 NA 
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Reference 
Study Design/ 
Population 
TMZ 
Pretreat-
ment  
Bevacizumab 
Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPF
S* 
(mo) 
mOS
* 
(mo) 
WHO Grade 3/4 
Toxicities (n) 
IV if receiving 
EIAED or if not, 
125 mg/m2, q2wk 
Vredenburg
h JJ et al92  
 
Phase 2  
Both cohorts: 
Median age 48 
y; 
Median 
number of 
progressions 2 
 
Yes Cohort 1: 
BEV 10 mg/kg IV 
q2wk 
+ 
CPT-11 340 mg/m2 
IV if receiving 
EIAED or if not, 
125 mg/m2, q2wk 
(6-wk cycle) 
 
Cohort 2: 
BEV 15 mg/kg IV 
q21d  
+ 
CPT-11 340 mg/m2 
IV if receiving 
EIAED or if not, 
125 mg/m2 on days 
1, 8, 22, and 29 (6-
wk cycle) 
23  
(35 
total) 
 
 
 
 
 
 
 
 
12 
NA 46c  5.6c 9.8c NA 
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Reference 
Study Design/ 
Population 
TMZ 
Pretreat-
ment  
Bevacizumab 
Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPF
S* 
(mo) 
mOS
* 
(mo) 
WHO Grade 3/4 
Toxicities (n) 
Reardon DA 
et al91  
 
Phase 2, open-
label 
 
Median age: 
54.3 y; 
1st relapse: 
52%; 
2nd relapse: 
30%;3rd 
relapse: 19% 
NA BEV 10 mg/kg IV 
q2w  
+ 
ETO 50 mg/m2 
daily for 21 
consecutive days 
each month 
27 CR: 1 
PR: 5 
SD: 19 
PD: 2 
44.4 4.2 10.8 Hematologic: 
15 
Nonhematologic:
17 (including 1 
grade 5 
thrombosis) 
[includes only 
those AEs that 
occurred in 
≥10% of pts] 
Stark-Vance 
V97  
NA NA BEV 5 mg/kg 
every other wk for 
2 doses  
+  
CPT-11 125 mg/m2 
qwk for 4 doses, 
followed by 2-wk 
rest period 
GB 11; 
10 
other 
glioma
s 
CR: 1a 
PR: 8a 
SD: 11a 
PD: 1a 
NA NA NA NA 
Pope WB et 
al93  
Retrospective 
database 
review 
NA BEV  
+ 
CP, CPT-11, or 
ETO 
[dosages NA] 
10 CR: 0 
PR: 4 
SD: 3 
PD: 3 
NA NA NA NA 
Norden AD 
et al95  
Retrospective 
analysis 
Jun 2005-Mar 
2007 
 
Yes BEV 10 m/kg (1 pt 
received 5 mg/kg) 
q2wk  
+ 
Chemotherapy: 
33 
 
NAb 42 NAb NAb NAb 
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Reference 
Study Design/ 
Population 
TMZ 
Pretreat-
ment  
Bevacizumab 
Regimen n 
Radio-
graphic 
Response 
(%) 
6-mo 
PFS* 
(%) 
mPF
S* 
(mo) 
mOS
* 
(mo) 
WHO Grade 3/4 
Toxicities (n) 
Median age 50 
y; 
Median KPS 
80 
CPT-11: n=47 
CP: n=6 
BCNU: n=1  
TMZ: n=1 
Gutin PH et 
al98  
Cohort study 
 
Median age 56 
y; 
Median KPS 
90 
NA BEV 10 mg/kg IV 
q2wk (28-day 
cycle) (median, 7 
cycles)  
+ 
30 Gy HFSRT in 5 
fractions after first 
BEV cycle 
20 NAb 65 7.3 12.5 NAb 
Abbreviations: AA, anaplastic astrocytoma; AUC, area under the curve; BCNU, carmustine; BEV, bevacizumab; CET, cetuximab; 
CP, carboplatin; CPT-11, irinotecan; CR, complete response; EIAED, enzyme-inducing antiepileptic drugs; ERL, erlotinib; ETO, 
etoposide; GB, glioblastoma; HFSRT, hypofractionated stereotactic reirradiation; inst, institution; IV, intravenous; mOS, median 
overall survival; mPFS, median progression-free survival; NA, not available; PD, progressive disease; PFS, progression-free survival; 
PR, partial response; pts, patients; SD, stable disease. 
For the most part, only glioblastoma data are presented in the table. We have reported enrollment numbers for different patient 
populations only when all data in a paper are presented for combined patient populations. 
*The disease progression-free survival and the overall survival were calculated from beginning of retreatment. 
a Data presented for glioblastoma patients only, except for Narayana 2009 study,88 where 37 patients had glioblastoma and 24 patients 
had anaplastic astrocytoma, and Stark-Vance et al,97 where 11 patients had glioblastoma and 10 had other high-grade gliomas.  
b Data not available because not presented separately for glioblastoma, anaplastic astrocytoma, and other glioma patients. 
c Data presented for both cohorts combined. 
